plasminogen

简明释义

英[plæzˈmɪnədʒən]美[ˌplæzˈmɪnədʒɪn]

n. [生化] 血纤维蛋白溶酶原

英英释义

单词用法

同义词

反义词

例句

1.Objective to study the relationship between plasminogen activator inhibitor type 1 (PAI 1) and biological behaviour of hepatocellular carcinoma (HCC).

目的研究纤溶酶原激活物抑制剂(PAI1)与肝细胞癌(HCC)生物学特性的关系。

2.Urokinase, a human plasminogen activator, is used clinically to promote the dissolution of thrombi.

尿激酶是一种纤溶酶原激活剂，临床上用于治疗血栓。

3.Method Plasminogen activator inhibitor-1(PAI-1) in 33 cases of diabetic nephropathy and 30 healthy controls were detected, and the test results were observed.

方法：检测33例糖尿病肾病患者及30例健康体检对照组血浆纤溶酶原激活物抑制物-1（PAI-1），观察检测结果。

4.We measured the plasminogen (PLG) content and plasmin (pl) activity in 54 leukemic patients.

对54例白血病患者进行血浆纤溶酶原(plg)及纤溶酶(PL)活性测定。

5.The enzyme showed strong fibrinolytic activity on fibrin and esterase activity in BAEE. It shows two effects, both acting on fibrin directly and activating plasminogen.

该酶具有强烈的纤溶活力和水解BAEE的活力，能直接作用纤维蛋白和间接激活纤溶酶原。

6.ObjectivesTo study the change of plasminogen activation system in different behavior type patients with coronary heart disease.

目的研究不同行为类型冠心病患者之间纤溶激活系统的变化。

7.Deficiency in plasminogen can lead to abnormal clotting disorders.

缺乏纤溶酶原可能导致异常的凝血障碍。

8.The enzyme that activates plasminogen is known as tissue plasminogen activator (tPA).

激活纤溶酶原的酶被称为组织纤溶酶原激活剂（tPA）。

9.The body converts plasminogen into plasmin during the healing process.

在愈合过程中，身体将纤溶酶原转化为纤溶酶。

10.In a laboratory setting, researchers study how plasminogen affects blood clotting.

在实验室环境中，研究人员研究纤溶酶原如何影响血液凝固。

11.Certain medications can enhance the activity of plasminogen to dissolve clots.

某些药物可以增强纤溶酶原的活性以溶解血块。

作文

In the realm of human biology, understanding the intricate mechanisms that govern our bodily functions is crucial. One such important component is plasminogen, a protein that plays a vital role in the body's ability to break down blood clots. The process of clot breakdown, known as fibrinolysis, is essential for maintaining proper blood flow and preventing complications associated with excessive clotting. Plasminogen is synthesized primarily in the liver and circulates in the bloodstream in an inactive form. When a blood clot forms, the body activates plasminogen into its active form, plasmin, which then works to dissolve the clot. This transformation is triggered by various factors, including tissue plasminogen activator (tPA), a substance released by endothelial cells lining the blood vessels.The significance of plasminogen extends beyond just the mechanics of clot dissolution. It is also involved in wound healing and tissue remodeling. After an injury, the body needs to ensure that blood clots are dissolved appropriately to allow for new tissue formation. Without the action of plasminogen and its conversion to plasmin, wounds could heal improperly, leading to chronic conditions or excessive scarring.Moreover, the regulation of plasminogen activation is critical for preventing pathological conditions. For instance, an overactive fibrinolytic system can lead to bleeding disorders, while insufficient plasminogen activity may result in thrombosis, where blood clots form excessively and block blood vessels. Therefore, maintaining a balance in plasminogen levels is essential for overall health.Research has shown that genetic variations can affect the levels and activity of plasminogen, which may predispose individuals to certain cardiovascular diseases. For example, mutations in the plasminogen gene can lead to dysregulation of this protein, increasing the risk of developing deep vein thrombosis or pulmonary embolism. Understanding these genetic factors can help in developing personalized treatment strategies for patients at risk.Furthermore, therapeutic applications involving plasminogen are being explored. In cases of acute myocardial infarction or ischemic stroke, where rapid restoration of blood flow is necessary, medications that enhance plasminogen activation can be life-saving. These thrombolytic agents work by promoting the conversion of plasminogen to plasmin, thus facilitating the breakdown of clots that obstruct blood vessels.In conclusion, plasminogen is not merely a passive component of the coagulation cascade but an active player in the delicate balance of hemostasis and tissue repair. Its role in the body highlights the complexity of biological systems and the importance of maintaining homeostasis. As research continues to unveil the multifaceted roles of plasminogen, it becomes increasingly clear that understanding such proteins is vital for advancing medical science and improving patient outcomes.

在人体生物学领域，理解调控我们身体功能的复杂机制至关重要。其中一个重要成分是纤溶酶原，这是一种在体内发挥重要作用的蛋白质，它有助于身体分解血块的能力。血块分解的过程称为纤溶，这对于维持正常的血流和防止过度凝血引发的并发症是必不可少的。纤溶酶原主要在肝脏合成，并以不活跃的形式在血液中循环。当血块形成时，身体会将纤溶酶原激活为其活跃形式——纤溶酶，后者则开始溶解血块。这一转化受到多种因素的触发，包括由血管内皮细胞释放的组织型纤溶酶原激活剂（tPA）。纤溶酶原的重要性不仅限于血块溶解的机制。它还参与伤口愈合和组织重塑。在受伤后，身体需要确保血块适当地被溶解，以便新的组织形成。如果没有纤溶酶原及其转化为纤溶酶的作用，伤口可能愈合不良，导致慢性病或过度瘢痕。此外，纤溶酶原激活的调节对预防病理状况至关重要。例如，过度活跃的纤溶系统可能导致出血障碍，而纤溶酶原活性不足则可能导致血栓形成，即血块过度形成并阻塞血管。因此，维持纤溶酶原水平的平衡对于整体健康至关重要。研究表明，遗传变异可能影响纤溶酶原的水平和活性，这可能使个体易患某些心血管疾病。例如，纤溶酶原基因中的突变可能导致该蛋白质的失调，从而增加发展深静脉血栓或肺栓塞的风险。理解这些遗传因素有助于为面临风险的患者制定个性化治疗策略。此外，涉及纤溶酶原的治疗应用也在探索中。在急性心肌梗死或缺血性中风等情况下，需要迅速恢复血流，增强纤溶酶原激活的药物可能挽救生命。这些溶栓剂通过促进纤溶酶原向纤溶酶的转化，从而促进破坏阻塞血管的血块。总之，纤溶酶原不仅仅是凝血级联反应的被动成分，而是止血和组织修复微妙平衡中的积极参与者。它在身体中的作用突显了生物系统的复杂性以及维持稳态的重要性。随着研究不断揭示纤溶酶原的多方面作用，越来越清楚的是，理解这些蛋白质对推动医学科学的发展和改善患者结果至关重要。